University of Pittsburgh

Sri International

Boston University

Medical University of South Carolina

Shufeng Liu

Tony Tianyi Wang

John A Porco, Jr

Fan Daping

Neil Lajkiewicz

Wenhan Zhang

Wenyu Wang

Tianyi Wang

Described herein are compounds, agents, compositions, and methods related to the treatment of a viral infection (e.g., Hepatitis C viral infection). In particular, the compounds, agents, compositions, and methods described herein inhibit viral entry into a target cell.

Compositions and methods for inhibiting viral infection

Disclosed herein are several apoplipoprotein E (ApoE) polypeptides, and nucleic acids encoding these polypeptides, that can be used to treat or prevent a hepatitis infection in a subject, such as a hepatitis C virus infection. These ApoE polypeptides can inhibit the entry of hepatitis C virus into cells, and inhibit viral replication. Nucleic acids encoding these polypeptides are also disclosed, as well as methods.

Apolipoprotein E polypeptides and their use

A rocaglamide or a rocaglate derivative, particularly aglaroxin C, blocks hepatitis C virus (HCV) entry with improved potency and therapeutic index.

Aglaroxin C and derivatives as HCV entry inhibitors

Disclosed herein are several apoplipoprotein E (ApoE) polypeptides, and nucleic acids encoding these polypeptides, that can be used to treat or prevent a hepatitis infection in a subject, such as a hepatitis C virus infection. These ApoE polypeptides can inhibit the entry of hepatitis C virus into cells, and inhibit viral replication. Nucleic acids encoding these polypeptides are also disclosed, as well as methods for their preparation.

Growing community of inventors

Pittsburgh, PA, United States of America

Shufeng Liu